3rd DOSE PRIMARY VACCINATION FOR SEVERELY IMMUNOCOMPROMISED
ATAGI recommends a 3rd primary dose of COVID-19 vaccine in severely immunocompromised populations to increase the likelihood their immune response is similar to that in the population after 2 doses. The lost of conditions and therapies is given in detail int eh folloiwng document
This is considered to be a 3-dose primary course and not a booster.
- all individuals aged ≥12 years with certain conditions or on therapies leading to severe immunocompromise receive this 3rd primary dose of a COVID-19 vaccine.
- An mRNA vaccine (Pfizer or Moderna) is preferred to Vaxzevria (AstraZeneca) for this 3rd dose.
- AstraZeneca can be used for the 3rd dose for individuals who have received AstraZeneca for their first 2 doses if there are no contraindications or precautions for use, or if a significant adverse reaction has occurred after a previous mRNA vaccine dose which contraindicates further doses of mRNA vaccine (e.g. anaphylaxis, myocarditis).
- The recommended interval for the 3rd dose is 2 to 6 months after the 2nd dose of vaccine.
- A minimum interval of 4 weeks may be considered in exceptional circumstances (e.g. anticipated intensification of immunosuppression; outbreaks).
- People who have received a 2nd dose more than 6 months ago should receive a 3rd dose as soon as feasible
If you meet this criteria don’t delay – get your dose soon.